A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients With Chronic Lymphoproliferative Disease.

Trial Profile

A Phase I, Sequential Cohort, Dose Escalation Trial to Determine the Safety, Tolerability, and Maximum Tolerated Dose of Weekly Administration of GRN163L in Patients With Chronic Lymphoproliferative Disease.

Completed
Phase of Trial: Phase I

Latest Information Update: 19 Apr 2014

At a glance

  • Drugs Imetelstat (Primary)
  • Indications B cell prolymphocytic leukaemia; Chronic lymphocytic leukaemia; Mantle-cell lymphoma; Non-Hodgkin's lymphoma; T cell prolymphocytic leukaemia; Waldenstrom's macroglobulinaemia
  • Focus Adverse reactions
  • Sponsors Geron Corporation
  • Most Recent Events

    • 18 Feb 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 10 Jan 2013 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
    • 24 Jan 2012 Planned end date changed from 1 Jun 2011 to 1 Mar 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top